GlassScriptPhysician profile
Sung Yoon Choo
NPI 1225037039
$9,740.61
in general payments reported to CMS, 2019-2025
31 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what a typical Blood Banking & Transfusion Medicine provider received nationally (typical 2025 total: $146).
See the full distribution for Blood Banking & Transfusion Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $125 · 2021: $893 · 2022: $1,433 · 2023: $1,886 · 2024: $2,667 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,912.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,728.68 | 2022-2025 | Reblozyl, Onureg, Opdivo |
| Genzyme Corporation | $998.22 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $914.49 | 2019-2023 | Ultomiris |
| Daiichi Sankyo INC. | $587.49 | 2023-2025 | Vanflyta, Injectafer, Enhertu |
| Exelixis INC. | $505.42 | 2019-2024 | Cabometyx |
| Janssen Biotech, INC. | $392.81 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $383.39 | 2022-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $374.82 | 2024-2025 | Jemperli |
| Incyte Corporation | $372.43 | 2019-2024 | Jakafi, Monjuvi |
| Emd Serono, INC. | $369.99 | 2023-2024 | Bavencio |
| Merck Sharp & Dohme LLC | $350.86 | 2024-2025 | Keytruda, Zerbaxa |
| Kite Pharma, INC. | $346.55 | 2023-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $249.97 | 2019-2023 | Libtayo |
| Sobi, INC | $167.73 | 2024 | |
| Amgen INC. | $150.00 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $150.00 | 2024 | |
| Legend Biotech USA INC. | $149.17 | 2025 | Carvykti |
| Seagen INC. | $148.87 | 2019 | |
| Abbvie INC. | $148.87 | 2025 | |
| Tg Therapeutics, INC. | $141.03 | 2022 | |
| Blueprint Medicines Corporation | $135.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $127.78 | 2024 | |
| Celgene Corporation | $125.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2023 | Tavalisse, Rezlidhia |
| Spectrum Pharmaceuticals INC. | $124.34 | 2019 | |
| Dova Pharmaceuticals | $120.94 | 2021 | |
| Jazz Pharmaceuticals INC. | $117.92 | 2019 | |
| Kadmon Pharmaceuticals LLC | $103.37 | 2021 | |
| Aveo Pharmaceuticals, INC. | $93.75 | 2022 | |
| Teleflex LLC | $22.27 | 2024 | Arrow |
| Terumo Bct, INC. | $14.45 | 2025 | Spectra Optia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Choo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.